Kate Burba

SAN DIEGO — Once-daily FXR314 was well-tolerated and safely improved liver fat content and biochemical markers over 16 weeks in patients with metabolic dysfunction-associated steatohepatitis, according to research at The Liver Meeting. “FXR314 is a novel, nonsteroidal non-bile acid [FXR (farnesoid X receptor)] agonist with a unique chemotype and functionality distinct from other FXR

SAN DIEGO — Increasing the mean arterial pressure target to 75 mmHg lowered the odds of 28-day mortality by 85%, and also reduced the odds of acute kidney injury nonrecovery, in decompensated cirrhosis with septic shock, according to data. “Maintaining a target mean arterial pressure (MAP), specifically a MAP greater than or equal to 65 mmHg, is central to the management of sepsis in

SAN DIEGO — Retreatment with nucleos(t)ide analogue therapy for relapse after withdrawal did not affect hepatitis B surface antigen seroclearance among patients with chronic HBV infection, according to a researcher at The Liver Meeting. “Nucleos(t)ide analogue (NA) therapy can effectively inhibit replication of HBV and improve clinical outcomes in individuals with chronic HBV

SAN DIEGO — Preemptive continuous renal replacement therapy after therapeutic plasma exchange reduced mortality and improved other outcomes in patients with acute liver failure and cerebral edema, according to data from The Liver Meeting. “In this part of the world, live-donor liver transplantation is the more active transplant program; however, it is not available because of the lack

PHILADELPHIA — Subcutaneous guselkumab outperformed placebo and, as with IV administration, appears to have “profound induction effects” on both clinical remission and endoscopic response in Crohn’s disease, a presenter told Healio. “Back at DDW, we presented the results of the GALAXI 2 and 3 study comparing guselkumab to not only placebo but to ustekinumab,”

PHILADELPHIA — Tirzepatide 15 mg produced similar weight loss results as bariatric surgery among patients with obesity but had a favorable safety profile, according to a presenter at the ACG Annual Scientific Meeting. “Bariatric surgery has been proven to be effective in not just achieving weight loss but also maintaining significant weight loss,” Jena Velji-Ibrahim, MD,

PHILADELPHIA — Rebyota was safe and effective at 8 weeks and up to 6 months in patients with recurrent Clostridioides difficile infection, many of whom had other gastrointestinal comorbidities and risk factors, according to data presented. “We showed a significant decrease in recurrence rates of Clostridioides difficile in a real-world population,” Timothy E. Ritter, MD, a

PHILADELPHIA — Although there was no overall increased risk for flare 1 year after gender-affirming hormone therapy in patients with inflammatory bowel disease, active IBD and receiving testosterone increased the likelihood of a flare. “Prior studies have shown there’s a similar prevalence of IBD in the cisgender and transgender patient populations, but little is known about IBD

PHILADELPHIA — Bezlotoxumab in combination with fecal microbiota transplantation did not further reduce recurrence of Clostridioides difficile infection in patients with inflammatory bowel disease, according to data presented here. “This was the first clinical trial to assess the clinical effect of FMT in combination with bezlotoxumab in patients with IBD and recurrent C. diff,”

OpenBiome will continue distribution of investigational fecal microbiota transplantation through 2024, as suspension may put certain patients with recurrent, refractory or fulminant Clostridioides difficile at risk, according to the AGA. “It is important to understand that the suspension is a voluntary action on the part of OpenBiome, which is the result of some communications they have